CARAVAGGIO
2020
Apixaban for the Treatment of Venous Thromboembolism Associated with Cancer
In 1,170 patients with cancer-associated venous thromboembolism, apixaban was non-inferior to dalteparin for recurrent VTE, without excess major bleeding.
Result
Efficacy: Recurrent venous thromboembolismHR 0.63
Below 1 favours apixaban, above 1 favours dalteparin.
- Absolute difference
- 2.3 points
The absolute difference is derived from the event rates.
Also reported: No excess gastrointestinal bleeding.
- Subtopic
- Venous thromboembolism
- Design
- Open-label, non-inferiority RCT
- Relevance
- Important: one of several pillars.
- Cited in
- ACC/AHA 2026 Pulmonary Embolism
- Source
- Agnelli G, et al. N Engl J Med. 2020;382(17):1599-1607.doi 10.1056/NEJMoa1915103
Discussion & critique
Unlike edoxaban (Hokusai-Cancer), apixaban showed no GI-bleeding signal; it is a preferred oral option in cancer-associated VTE, including gastrointestinal tumours.